| Rivaroxaban with or without aspirin in stable cardiovascular disease JW Eikelboom, SJ Connolly, J Bosch, GR Dagenais, RG Hart, ... New England Journal of Medicine 377 (14), 1319-1330, 2017 | 2371 | 2017 |
| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2259 | 2019 |
| Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study MJ O'Donnell, SL Chin, S Rangarajan, D Xavier, L Liu, H Zhang, ... The lancet 388 (10046), 761-775, 2016 | 2157 | 2016 |
| EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries K Kotseva, D Wood, D De Bacquer, G De Backer, L Rydén, C Jennings, ... European journal of preventive cardiology 23 (6), 636-648, 2016 | 1298 | 2016 |
| Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial SS Anand, J Bosch, JW Eikelboom, SJ Connolly, R Diaz, P Widimsky, ... The Lancet 391 (10117), 219-229, 2018 | 930 | 2018 |
| Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry K Kotseva, G De Backer, D De Bacquer, L Rydén, A Hoes, D Grobbee, ... European journal of preventive cardiology 26 (8), 824-835, 2019 | 796 | 2019 |
| Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy … MF Piepoli, U Corrà, S Adamopoulos, W Benzer, B Bjarnason-Wehrens, ... European journal of preventive cardiology 21 (6), 664-681, 2014 | 719 | 2014 |
| Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 131-138, 2019 | 532 | 2019 |
| Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin P Moayyedi, JW Eikelboom, J Bosch, SJ Connolly, L Dyal, ... Gastroenterology 157 (3), 682-691. e2, 2019 | 407 | 2019 |
| Кардиоваскулярная профилактика 2017. Российские национальные рекомендации СА Бойцов, НВ Погосова, МГ Бубнова, ОМ Драпкина, НЕ Гаврилова, ... Российский кардиологический журнал, 7-122, 2018 | 373 | 2018 |
| Psychosocial aspects in cardiac rehabilitation: From theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular … N Pogosova, H Saner, SS Pedersen, ME Cupples, H McGee, S Höfer, ... European journal of preventive cardiology 22 (10), 1290-1306, 2015 | 367 | 2015 |
| Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries G De Backer, P Jankowski, K Kotseva, E Mirrakhimov, Ž Reiner, L Ryden, ... Atherosclerosis 285, 135-146, 2019 | 304 | 2019 |
| Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary … K Kotseva, D De Bacquer, G De Backer, L Rydén, C Jennings, V Gyberg, ... European journal of preventive cardiology 23 (18), 2007-2018, 2016 | 217 | 2016 |
| INTERSTROKE investigators. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study MJ O’Donnell, SL Chin, S Rangarajan, D Xavier, L Liu, H Zhang, ... Lancet 388 (10046), 761-75, 2016 | 215 | 2016 |
| Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular … HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... Diabetes, Obesity and Metabolism 20 (1), 42-49, 2018 | 196 | 2018 |
| Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial J Bosch, JW Eikelboom, SJ Connolly, NC Bruns, V Lanius, F Yuan, ... Canadian Journal of Cardiology 33 (8), 1027-1035, 2017 | 193 | 2017 |
| Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial P Moayyedi, JW Eikelboom, J Bosch, SJ Connolly, L Dyal, ... Gastroenterology 157 (2), 403-412. e5, 2019 | 160 | 2019 |
| Psychosocial risk factors in relation to other cardiovascular risk factors in coronary heart disease: Results from the EUROASPIRE IV survey. A registry from the European … N Pogosova, K Kotseva, D De Bacquer, R von Känel, D De Smedt, ... European journal of preventive cardiology 24 (13), 1371-1380, 2017 | 157 | 2017 |
| Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial T Cukierman-Yaffe, HC Gerstein, HM Colhoun, R Diaz, LE García-Pérez, ... The Lancet Neurology 19 (7), 582-590, 2020 | 156 | 2020 |
| Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme … K Kotseva, G De Backer, D De Bacquer, L Rydén, A Hoes, D Grobbee, ... European journal of preventive cardiology 28 (4), 370-379, 2021 | 149 | 2021 |
